Viking Therapeutics Faces Mounting Losses Amid Aggressive Drug Development Push

Investors in Viking Therapeutics were met with sobering financial results for the third quarter of 2025, as the biotechnology firm reported a dramatic widening of its net loss. The company’s shortfall reached $90.8 million, representing a staggering 264 percent increase compared to the same period last year. This substantial jump stems primarily from escalating development expenses for its weight loss treatment candidate, VK2735.

The depth of Viking’s financial challenges became evident as the company reported a per-share loss of $0.81, significantly underperforming against analyst consensus estimates that had projected a loss of $0.67 per share. Research and development spending surged to $90 million, marking a 294 percent year-over-year increase that reflects the company’s aggressive expansion of Read more...